GSK sponsors 2025 National Senior Games as part of Sideline RSV campaign to raise awareness of RSV in older adults ...

GSK is taking to the airwaves to get the message out about respiratory syncytial virus (RSV), presenting a TV special about how the pathogen has affected athletes in the upcoming National Senior Games ...

British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

GSK plc (GSK) said on Monday that its application for extending the use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults aged 18-49 who are at increased risk of contracting the ...

The ACIP has now recommended the use of GSK’s RSV vaccine, Arexvy, and PFE’s RSV vaccine, Abrysvo, in adults aged 50-59 who are at high risk of severe RSV disease.

London: GSK plc has announced that the US Food and Drug Administration (FDA) has accepted for review an application to extend ...

In 2023, an average of 440,000 people per week received RSV vaccines from GSK and Pfizer in September, with 65% opting for GSK’s Arexvy. However, this September, the weekly average fell to 157,000.

The CDC recently updated RSV vaccine recommendations to include certain adults aged 50 and up. When is the best time to get ...

The Food and Drug Administration on Wednesday approved the world’s first RSV vaccine: a shot for adults ages 60 and up, made by pharmaceutical giant GSK. The milestone was decades in the making .

GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a Phase 3 trial. Read more here.